miRNAs, which were discovered only 15 years ago, are short sequences of nucleotides that occur naturally within cells. It is estimated that there are about …(read more)
Related Posts
Servier and Miragen Sign $352 Million Partnership Agreement for the Research, Development and Commercialization of MicroRNA-targeting Drugs for Cardiovascular Disease 
NIH Ponies Up for miRNA Research
Yale spinout 3PrimiR pulls in $2M in funding
miRNAs’ Therapeutic Potential
First microRNA Targeted Drug Reaches Phase II Clinical Trial
RXi Pharmaceuticals Announces Positive Initial Results in microRNA Therapeutics
Related posts:
- RXi Pharmaceuticals and miRagen Therapeutics Announce Formation of Research Collaboration in the Field of microRNA
- miRagen Therapeutics Named 2009 Rising Star of the Year by Colorado BioScience Association
- miRagen Therapeutics Named University of Colorado Technology Transfer Office Bioscience Company of the Year
- Servier and Miragen Sign $352 Million Partnership Agreement for the Research, Development and Commercialization of MicroRNA-targeting Drugs for Cardiovascular Disease
- miRagen Therapeutics and t2cure Sign Licensing Agreement for microRNA Target Implicated in Vascular Disease
Loading ...
